The true overall mortality of unselected nephropathic type 2 diabetic patients with mild to moderate renal insufficiency.
Biesenbach
Georg
G
Janko
Otmar
O
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000401:mortality*; D003928:Diabetic Nephropathies / Q000097:blood / Q000401:mortality*; D006801:Humans; D000077405:Irbesartan; D018579:Patient Selection; D015996:Survival Rate; D013777:Tetrazoles / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D003404:Creatinine; D000077405:Irbesartan